Removing barriers to participation in clinical trials, a conceptual framework and retrospective chart review study

被引:24
|
作者
Kanarek, Norma F. [1 ,2 ]
Kanarek, Marty S. [3 ,4 ]
Olatoye, Dare [5 ]
Carducci, Michael A. [6 ]
机构
[1] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21205 USA
[2] Johns Hopkins Sch Med, Dept Oncol, Baltimore, MD 21205 USA
[3] Univ Wisconsin Madison, Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI 53726 USA
[4] Univ Wisconsin Madison, Nelson Inst Environm Studies, Madison, WI 53726 USA
[5] Johns Hopkins Sch Med, Baltimore, MD 21205 USA
[6] Johns Hopkins Sch Med, Dept Oncol Urol Oncol, Baltimore, MD USA
来源
TRIALS | 2012年 / 13卷
关键词
Justice; Beneficence; Respect for persons; Clinical trials; Clinical trial accrual; Prostate cancer; Barriers to clinical trials; Disparities; Framework; PROSTATE-SPECIFIC ANTIGEN; COMPREHENSIVE CANCER CENTER; INFORMED-CONSENT; RANDOMIZED-TRIALS; PATIENT INTEREST; DECISION-MAKING; BREAST-CANCER; WORKING GROUP; IMPACT; ENROLLMENT;
D O I
10.1186/1745-6215-13-237
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: Enrollment in interventional therapeutic clinical trials is a small fraction of all patients who might participate given reasonable access. Methods: A hierarchical approach is utilized in measuring staged participation from trial availability to patient enrollment. Our framework suggests that concern for justice comes in the design and eligibility criteria for clinical trials; attention to beneficence is given in the eligibility and physician triage stages. The remaining four stages rely on respect for persons. An example is given where reasons for nonparticipation or barriers to participation in prostate cancer clinical trials are examined within the framework. In addition, medical oncology patients with an initial six month consultation are tracked from one stage to the next by race using the framework to assess participation comparability. Results: We illustrated seven transitions from being a patient to enrollment in a clinical trial in a small study of prostate cancer cases who consulted SKCCC Medical Oncology Department in early 2010. Pilot data suggest transition probabilities as follows: 65% availability, 84% eligibility, 92% patient triage, 89% trials discussed, 45% patient interested, 63% patient consented, and 92% patient enrolled. The average transition probability was 77.7%. The average transition probability, patient-trial-fit was 50%; opportunity was 51%, and acceptance was 66.7%. Trial availability, patient interest and patient consented were three transitions that were below the average; none were statistically significant. Conclusions: The framework may serve to streamline comprehensive reporting of clinical trial participation to the benefit of patients and the ethical conduct of clinical trials.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Removing barriers to participation in clinical trials, a conceptual framework and retrospective chart review study
    Norma F Kanarek
    Marty S Kanarek
    Dare Olatoye
    Michael A Carducci
    [J]. Trials, 13
  • [2] Barriers to participation in clinical trials
    Clayton, Harriet
    Grant, Pauline
    [J]. MOLECULAR GENETICS AND METABOLISM, 2023, 138 (02) : 27 - 27
  • [3] Applying a Conceptual Framework to Maximize the Participation of Diverse Populations in Cancer Clinical Trials
    Napoles, A.
    Cook, E.
    Ginossar, T.
    Knight, K. D.
    Ford, M. E.
    [J]. CANCER DISPARITIES, 2017, 133 : 77 - 94
  • [4] Motivation and barriers to participation in clinical trials
    Gaul, Charly
    Schmidt, Thomas
    Helm, Juergen
    Hoyer, Heike
    Haerting, Johannes
    [J]. MEDIZINISCHE KLINIK, 2006, 101 (11) : 873 - 879
  • [5] Barriers to participation in clinical trials: a physician survey
    Mahmud, A.
    Zalay, O.
    Springer, A.
    Arts, K.
    Eisenhauer, E.
    [J]. CURRENT ONCOLOGY, 2018, 25 (02) : 119 - 125
  • [6] Breaking barriers to participation in cancer clinical trials
    Finn, R
    [J]. SCIENTIST, 2000, 14 (04): : 14 - 14
  • [8] Barriers to participation in cancer prevention clinical trials
    Hall, Michael J.
    Egleston, Brian
    Miller, Suzanne M.
    Buzaglo, Joanne S.
    Millard, Jennifer
    Ridgway, Caroline
    Damjanov, Nevena
    Sprandio, John D.
    Meropol, Neal J.
    [J]. ACTA ONCOLOGICA, 2010, 49 (06) : 757 - 766
  • [9] BARRIERS AND FACILITATORS TO PARTICIPATION OF MINORITIES IN CLINICAL TRIALS
    Schmotzer, Geri L.
    [J]. ETHNICITY & DISEASE, 2012, 22 (02) : 226 - 230
  • [10] Older adult participation in cancer clinical trials: A systematic review of barriers and interventions
    Sedrak, Mina S.
    Freedman, Rachel A.
    Cohen, Harvey J.
    Muss, Hyman B.
    Jatoi, Aminah
    Klepin, Heidi D.
    Wildes, Tanya M.
    Le-Rademacher, Jennifer G.
    Kimmick, Gretchen G.
    Tew, William P.
    George, Kevin
    Padam, Simran
    Liu, Jennifer
    Wong, Andrew R.
    Lynch, Andrea
    Djulbegovic, Benjamin
    Mohile, Supriya G.
    Dale, William
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2021, 71 (01) : 78 - 92